Status:
RECRUITING
Cannabidiol, Morphine, Pain
Lead Sponsor:
Wayne State University
Conditions:
CBD
Chronic Pain
Eligibility:
All Genders
18-55 years
Phase:
PHASE1
Brief Summary
The purpose of the proposed study is to investigate the interaction of cannabidiol (CBD) and morphine effects on pain sensitivity. Cannabidiol is a cannabinoid (similar to cannabis, or marijuana) pres...
Detailed Description
Eligible participants will be asked to participate in a total of three experimental sessions with each session day separated by at least one week. Each session day will last approximately 6-7 hours. ...
Eligibility Criteria
Inclusion
- Participants must report having smoked a cigarette (nicotine or marijuana) AND having taken an opioid on 3 or more occasions in their lifetime.
- Participants must be in good health to participate; those with certain contraindications will be excluded.
- All participants will undergo psychiatric evaluation and will be asked to report their substance use history by interview and structured questionnaire methods.
- Participants will undergo medical evaluations using medical history, physical exam, standard lab tests (complete blood chemistry, urinalysis, urine pregnancy test for females), and 12-lead ECG.
Exclusion
- Serious psychiatric illness (e.g. psychotic or bipolar disorder, recent suicide attempts; severe depression)
- Substance Use Disorders other than Nicotine Use Disorder and Mild Cannabis Use Disorder
- Neurological diseases; cardiovascular problems (e.g. systolic BP \>140 or \<95 mmHg, diastolic BP \>90 mmHg, abnormal ECG); pulmonary diseases; systemic diseases (e.g. liver, renal, inflammatory)
- Cognitive impairment (\<80 IQ)
- Past-month medications that increase study risk
- Women who are pregnant (urine HCG), lactating (self-report), or if heterosexually active and not using (self-report) medically approved birth control (oral or depot contraception, IUD, condom/foam, sterilization, tubal ligation)
- Individuals unable to give informed consent will be excluded.
Key Trial Info
Start Date :
May 1 2019
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
January 26 2025
Estimated Enrollment :
40 Patients enrolled
Trial Details
Trial ID
NCT04030442
Start Date
May 1 2019
End Date
January 26 2025
Last Update
February 29 2024
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Tolan Park Medical Building
Detroit, Michigan, United States, 48201